|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 31/00 | |
| C07K 14/47 | |||
| C07K 16/18 | |||
| C07K 16/28 | |||
| C07K 16/40 | |||
| A61P 35/00 |
| (11) | Number of the document | 3326622 |
| (13) | Kind of document | T |
| (96) | European patent application number | 17196662.5 |
| Date of filing the European patent application | 2013-12-12 | |
| (97) | Date of publication of the European application | 2018-05-30 |
| (45) | Date of publication and mention of the grant of the patent | 2021-01-20 |
| (46) | Date of publication of the claims translation |
| (30) | Number | Date | Country code |
| 201261737276 P | 2012-12-14 | US |
| (72) |
GIACCIA, Amato J., US
RANKIN, Erinn Bruno, US
COCHRAN, Jennifer R., US
JONES, Douglas, US
KARIOLIS, Mihalis, US
FUH, Katherine, US
MIAO, Yu, US
HERSHENSON, Susan, US
|
| (73) |
The Board of Trustees of the Leland Stanford Junior University,
Office of the General Counsel Building 170, Third Floor, Main Quad P.O. Box 20386, Stanford, CA 94305-2038,
US
Aravive Biologics, Inc., River Oaks Tower 3730 Kirby Drive, Suite 1200, Houston, TX 77098, US |
| (54) | MODIFIED AXL PEPTIDES AND THEIR USE IN INHIBITION OF AXL SIGNALING IN ANTI-METASTATIC THERAPY |
| MODIFIED AXL PEPTIDES AND THEIR USE IN INHIBITION OF AXL SIGNALING IN ANTI-METASTATIC THERAPY |